CVE-2022-23512

Public Exploit
Metersphere is vulnerable to Path Injection.

Description

MeterSphere is a one-stop open source continuous testing platform. Versions prior to 2.4.1 are vulnerable to Path Injection in ApiTestCaseService::deleteBodyFiles which takes a user-controlled string id and passes it to ApiTestCaseService, which uses the user-provided value (testId) in new File(BODY_FILE_DIR + "/" + testId), being deleted later by file.delete(). By adding some camouflage parameters to the url, an attacker can target files on the server. The vulnerability has been fixed in v2.4.1.

Category

7.7
CVSS
Severity: High
CVSS 3.1 •
EPSS 0.09%
Third-Party Advisory github.com
Affected: metersphere metersphere
Published at:
Updated at:

References

Link Tags
https://github.com/metersphere/metersphere/security/advisories/GHSA-5mwp-xw7p-5j27 patch third party advisory exploit

Frequently Asked Questions

What is the severity of CVE-2022-23512?
CVE-2022-23512 has been scored as a high severity vulnerability.
How to fix CVE-2022-23512?
To fix CVE-2022-23512, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2022-23512 being actively exploited in the wild?
It is possible that CVE-2022-23512 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2022-23512?
CVE-2022-23512 affects metersphere metersphere.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.